Mumbai, November 12, 2025: Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin Limited, has inaugurated a dedicated oncology block at its Vizag facility in India, marking a major expansion of its high-potent active pharmaceutical ingredient (HPAPI) manufacturing capabilities.
Spanning 4,270 square meters, the new high-containment facility features 20 reactors (250L–2000L), over 20 isolators, and advanced containment systems maintaining exposure levels below 0.05 µg/m³. Designed for flexible scale-up (1–35 kg batch range) and environmental control, it enables safe and compliant production of oncology APIs that meet global quality standards.
Dr. Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions, said the new unit underscores Lupin’s commitment to advancing oncology research and manufacturing. “This marks a major milestone in LMS’s evolution into a trusted CDMO partner for oncology innovators,” he noted.
The Vizag oncology block integrates process development, analytical research, and quality control within one setup, ensuring seamless transition from lab-scale synthesis to full-scale commercial manufacturing. The facility also includes isolator-based operations, integrated SCADA systems, and a robust effluent detoxification system aligned with global regulatory norms.
With this launch, Lupin strengthens its position as a global CDMO partner for oncology innovators, combining scientific rigor, containment excellence, and regulatory expertise to support faster and safer oncology drug development from concept to commercialization.
